Edition:
United States

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

1.19USD
13 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.19
Open
--
Day's High
--
Day's Low
--
Volume
1,600
Avg. Vol
47,645
52-wk High
$3.06
52-wk Low
$1.13

Latest Key Developments (Source: Significant Developments)

Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial of CLR 131
Wednesday, 6 Dec 2017 08:00am EST 

Dec 6 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR ANNOUNCES EXPANSION OF RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN PHASE 2 TRIAL OF CLR 131.CELLECTAR BIOSCIENCES - WILL INCREASE TARGETED PATIENT ENROLLMENT IN R/R MULTIPLE MYELOMA COHORT OF CO'S CURRENTLY ENROLLING CLR 131 PHASE 2 CLINICAL TRIAL.  Full Article

Cellectar Biosciences posts Q3 loss of $0.26 per share
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences reports third quarter 2017 financial and corporate performance.Q3 loss per share $0.26.Cash and cash equivalents as of September 30, 2017 were about $5.7 million​.  Full Article

Cellectar updates median overall survival from phase 1 trial in advanced multiple myeloma
Tuesday, 7 Nov 2017 08:30am EST 

Nov 7 (Reuters) - Cellectar Biosciences Inc ::Cellectar announces updated median overall survival of 26.2 months from cohort 1 of clr 131 phase 1 trial in advanced multiple myeloma.  Full Article

Cellectar Biosciences gets additional patent for CLR 131, CLR 125 in Japan
Tuesday, 17 Oct 2017 08:30am EDT 

Oct 17 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences receives additional Japanese patent for CLR 131 and CLR 125 for the treatment of various solid tumors.Japanese patent office granted it a patent covering both composition of matter and method of use for CLR 131 and CLR 125​.  Full Article

Cellectar Biosciences and Pierre Fabre extend collaboration
Tuesday, 10 Oct 2017 07:30am EDT 

Oct 10 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences and Pierre Fabre extend collaboration for development of new phospholipid drug conjugates.Cellectar Biosciences - ‍aim of extension is to further evaluate synergistic effects observed when Cellectar's phospholipid ethers are combined with Pierre Fabre's novel cytotoxic payloads​.Cellectar Biosciences - ‍program teams will continue to evaluate the new PDC compounds.  Full Article

Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics
Thursday, 21 Sep 2017 08:30am EDT 

Sept 21 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics to develop new phospholipid drug conjugates.Cellectar Biosciences Inc - financial terms of collaboration have not been disclosed.Cellectar Biosciences - ‍under terms of collaboration, Onconova will provide Cellectar with several compounds, including some from family of molecules that contains briciclib​.Cellectar Biosciences Inc - both companies will have option to advance development of any of newly conjugated PDC molecules.  Full Article

Cellectar Biosciences Inc's Chad J. Kolean gave notice to co of his resignation as CFO
Friday, 18 Aug 2017 05:25pm EDT 

Aug 18 (Reuters) - Cellectar Biosciences Inc ::Cellectar Biosciences Inc - Chad J. Kolean gave notice to co of his resignation as vice president, CFO, treasurer of co, effective September 5, 2017.Cellectar Biosciences Inc - appointed John P. Hamill as interim Chief Financial Officer of company .  Full Article

Cellectar Biosciences reports Q2 loss per share $0.23
Monday, 14 Aug 2017 04:45pm EDT 

Aug 14 (Reuters) - Cellectar Biosciences Inc -:Cellectar Biosciences reports second quarter 2017 financial and corporate performance.Q2 loss per share $0.23.Cellectar Biosciences Inc - ‍estimates that available cash and cash equivalents will fund its planned operations into Q2 of 2018​.Cellectar Biosciences Inc - ‍additional capital will be required for operations beyond Q2 of 2018​.  Full Article

Cellectar Biosciences signs collaboration with Avicenna Oncology to develop new PDCs for solid tumors
Tuesday, 1 Aug 2017 08:30am EDT 

Aug 1 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences signs collaboration with avicenna oncology to develop new PDCs for solid tumors.Cellectar Biosciences Inc says financial terms of collaboration have not been disclosed..Cellectar Biosciences Inc says co will oversee in vitro and in vivo testing of these molecules alongside an antibody drug conjugate with same payload.Says under terms of research collaboration, Avicenna will provide their novel payloads to cellectar.Cellectar Biosciences Inc says both companies will have option to advance development of any of newly conjugated molecules.  Full Article

Cellectar Biosciences files for mixed shelf of up to $50 mln
Monday, 5 Jun 2017 05:16pm EDT 

June 5 (Reuters) - Cellectar Biosciences Inc ::Cellectar Biosciences Inc files for mixed shelf of up to $50 million - sec filing.  Full Article

BRIEF-Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial of CLR 131

* CELLECTAR ANNOUNCES EXPANSION OF RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN PHASE 2 TRIAL OF CLR 131